Dapagliflozin after transcatheter aortic valve implantation for aortic stenosis significantly decreases the risk for death or worsening heart failure versus standard care.
Surgical intervention is typically used to treat HCM with severe mitral regurgitation but can be high risk. MitraClip combined with PTSBME was successfully performed in this patient with obstructive HCM and severe MR.
TAVR use has increased in low-risk patients, but serious complications can still occur. An elderly patient underwent TAVR to treat severe bicuspid aortic valve stenosis but experienced multiple strokes 6 months later.
The addition of tricuspid transcatheter edge-to-edge repair to optimized medical therapy for severe tricuspid regurgitation improves clinical and patient-reported outcomes.
An expert-led symposium exploring the most pertinent issues in cardio-oncology, with a focus on the new ESC guidelines. Highlights include preventative approaches in cardio-oncology, toxicity risk-stratification strategies, the clinical management of myocarditis as an adverse effect of immune checkpoint inhibitor-treatments, and the utility of biomarkers in long-term follow-up of cardiovascular disease risk in cancer patients.
Surgical intervention is typically used to treat HCM with severe mitral regurgitation but can be high risk. MitraClip combined with PTSBME was successfully performed in this patient with obstructive HCM and severe MR.
TAVR use has increased in low-risk patients, but serious complications can still occur. An elderly patient underwent TAVR to treat severe bicuspid aortic valve stenosis but experienced multiple strokes 6 months later.
Severe cardiomyopathy presenting 20 years after anthracycline treatment for non-Hodgkin’s lymphoma during early adulthood. The patient's worsening heart failure was successfully managed with multidrug treatment with add-on vericiguat and ivabradine based on quadruple therapy.
Originally, trans-catheter aortic valve implantation (TAVI) was reserved for patients in whom surgical aortic valve replacement was contra-indicated; however, it is increasingly used in younger and lower-risk patients [ 1 – 3 ]. TAVI candidates …
Transcatheter Aortic Valve Replacement (TAVR), also known as Transcatheter Aortic Valve Implantation (TAVI), is a leading minimally invasive interventional operation to treat patients with aortic stenosis [ 1 ]. In 2002, the world’s first TAVR …
Many acute and chronic conditions, such as traditional CVD risk factors, emotional/physical stress, autoimmune diseases, microbial/viral infections and ageing, can provoke endothelial alterations. This promotes a low-grade inflammation, which …
Delivering valvular intervention for all eligible patients with valvular heart disease (VHD) in a timely manner remains a challenge. Therefore, a high number of patients with heart failure (HF) and VHD receive pharmacotherapy while awaiting …
With an estimated population-wide prevalence of 0.5%, and prevalences of 2–9% in populations aged over 75 years [ 1 ], aortic valve stenosis (AVS) constitutes the most common acquired cardiac valve dysfunction and is understood to be the …
Diagnosis of aortic valve stenosis (AS) is performed manually by a physician experienced in echocardiography imaging. A specific subtype of AS, a severe low-gradient AS, is the most challenging one in terms of differentiating it from the moderate …
Transcatheter aortic valve replacement (TAVR) has emerged as an alternative to surgical aortic valve replacement (SAVR) for the majority of patients with severe symptomatic aortic valve stenosis (AS) across the whole spectrum of surgical risk [ 1 …2
Aortic valve stenosis (AS) is one of the most common valvular heart disorders and the prevalence is expected to further increase as the population ages. Once symptomatic, patients with severe AS have significantly increased rates of morbidity and …
